USD 36.4 billion
Lung Cancer Therapeutics Market Size, Share, and Growth Analysis
Lung Cancer Therapeutics Market By Therapy (Radiation Therapy, Targeted Therapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Type of Molecule, By Distribution Channel, By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35J2088 |
Region:
Global |
Published Date: May, 2025
Pages:
242
|Tables:
122
|Figures:
77
Format -
Lung Cancer Therapeutics Market Insights
Global Lung Cancer Therapeutics Market size was valued at USD 36.4 billion in 2023 and is poised to grow from USD 41.2 billion in 2024 to USD 111.1 billion by 2032, growing at a CAGR of 13.2% during the forecast period (2025-2032).
The development of new medical diagnostic techniques, innovative medicines, and heightened awareness of lung cancer in both developed and developing nations have all contributed to an increase in lung cancer treatments. Thus, the lung cancer therapeutics market growth is being driven by these factors. Governments' increased efforts and investments to develop healthcare infrastructure and offer high-quality treatment alternatives are expected to fuel the expansion of the global lung cancer therapeutics market. Additionally, people's growing awareness of the variety of lung cancer treatment options is one of the main factors propelling market rise.
Furthermore, during the lung cancer therapeutics market forecast period, the growth rate is expected to be supported by factors such as growing disposable income, continuous research and development to create new technologies, the introduction of the most recent radiation therapy technology, and the expanding economies in developing and underdeveloped nations. In order to improve patient treatment outcomes, current market participants in the global market are concentrating on ongoing innovation and portfolio upgrades with new and effective product offerings. One of the most prevalent types of cancer in the world, lung cancer is responsible for a considerable number of fatalities globally.
US Lung Cancer Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Non-Small Cell Lung Cancer (NSCLC)
Fastest Growth
Small Cell Lung Cancer (SCLC)
Growth Rate
13.2% CAGR
Global Lung Cancer Therapeutics Market ($ Bn)
Country Share by North America (%)
To get more reports on the above market click here to Buy The Report
Lung Cancer Therapeutics Market Segments Analysis
Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User and region. Based on Therapy, the market is segmented into Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Others. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Based on Type of Molecule, the market is segmented into Small molecules and Biologics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Disease Type
As per categorization by disease type, the market is classified as non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Among these, the non-small cell lung cancer (NSCLC) earned the largest share and continues to dominate the lung cancer therapeutics market share. Non-small cell lung cancer (NSCLC) dominates the global lung cancer therapeutics market due to its prevalence, accounting for approximately 85% of all lung cancer cases. Advancements in example therapies and immunotherapy in recent times has contributed to improved outcomes among patients hence increasing the need for advanced treatment methods. The advent of precision medicine with an emphasis on the development of biomarkers has also transformed the treatment options available for patients thus making non-small cell lung cancer a major focus area for pharmaceutical industry investment and driving the strong growth of the market.
Small cell lung cancer (SCLC) is poised to become the fastest-growing segment in the global lung cancer therapeutics industry, due to its aggressive nature and the urgent need for effective treatment options. The market for lung cancer therapeutics is virtually dominated by non-small cell lung cancer (NSCLC) due to its high incidence, which contributes nearly 85% of every other lung cancer case. The recent advancements in targeted therapy and Immunotherapy have worked wonders in the quality of care offered to the patients, thus, increases the need for better therapies. Precision medicine and biomarker development have transformed the treatment landscape even further, making NSCLC a target of interest for cutting-edge drug development which further fuels market growth.
Analysis by Treatment
Chemotherapy remains a cornerstone of treatment in the global lung cancer therapeutics industry, particularly for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Recent improvements consist of the creation of specific combination treatment strategies with an emphasis on efficacy and resistance minimization. New developments in the field of personalized medicine are also optimizing chemotherapy according to the characteristics of the patients and their tumors. This is due to chemotherapy is simply the best line of treatment for breakthrough cancer due to its capability to attack quickly dividing cancerous cells, which translates to great potential benefits to the patients. Although there has been an increase in the use of immunotherapies and targeted treatments, chemotherapy is still crucial due to the fact that it has been the mainstay treatment for the advanced stages and for palliative care.
Radiotherapy is set to be the fastest-growing segment in the global lung cancer therapeutics industry, due to its evolving role in both curative and palliative care for lung cancer patients. Therapeutic Modality SBRT, Treatment Planning and Delivery Techniques, Computer and Image Systems and their Applications, Enhance the Quality and Outcome of Treatment with Less Harm to the Adjacent Normal Structures. Furthermore, the combination of radiotherapy with immunotherapy is increasing its efficiency and inspiring more attention from clinicians and sponsors. Given the rising trend for patients to prefer treatment options that are less invasive and more focal, the capability of radiotherapy in providing effective control of the disease over the tumors renders it an attractive segment in the treatment of lung cancer.
Global Lung Cancer Therapeutics Market By Disease Type (%)
To get detailed analysis on other segments, Request For Free Sample Report
Lung Cancer Therapeutics Market Regional Insights
North America dominates the global lung cancer therapeutics market outlook due to several key factors, including advanced healthcare infrastructure, significant investment in research and development, and a high prevalence of lung cancer. Drug development and clinical trials are also on the increase owing to the presence of top pharmaceutical companies and biotechnology firms, which introduces a consistent flow of new therapies. In addition, robust cancer treatment regulation as well as health insurance for cancer treatment encourages the patients to access advanced treatment. The rising levels of awareness on lung cancer together with increased focus on early-stage diagnosis as well as personalized treatment plans also explains how the region adheres to the dynamic market quite effectively.
The Asia-Pacific region is the fastest-growing market for global lung cancer therapeutics market due to a combination of rising lung cancer incidence rates and increasing investments in healthcare infrastructure. Increasing population density, contamination, and lifestyle changes have led to the prevalence of lung cancer with an emphasis on the need of looking for better ways of treatment. Furthermore, cancer treatment has become a priority for many governments thus access to new medicines or experimental therapies is improving. In addition, the rising employment of technologies and growing presence of pharmaceutical companies in developing lung cancer therapeutics industry catalyze the growth. It is in this context that a strong pipeline of new therapies is being developed, making the Asia-Pacific region an important lung cancer therapeutics region in the world.
Global Lung Cancer Therapeutics Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Lung Cancer Therapeutics Market Dynamics
Lung Cancer Therapeutics Market Drivers
Increasing Incidence of Lung Cancer
- The increasing lung cancer all over the globe is one of the major factors driving the global lung cancer therapeutics market trends. Tobacco consumption, environmental contamination, and evolution in lifestyle are some of the key factors resulting in the increase in the number of diagnosed cases, thus, resulting in increased demand for effective treatment methods and new therapies to improve patient care.
Advancements in Treatment Technologies
- Treatment technologies, including targeted therapies and immunotherapies, are changing the therapeutic landscape of lung cancer, this is most especially the case, for good reasons. They come with better efficacy and fewer side effects than the existing models. Furthermore, due to ongoing research and development of new treatment options, the health services also assist to customize treatment plans more effectively, which in turn leads to further expansion of the global lung cancer therapeutics market share by higher acceptance of patients.
Lung Cancer Therapeutics Market Restraints
Stringent Regulatory Approvals
- Stringent regulatory requirements for the approval of new lung cancer therapies can hinder the lung cancer therapeutics industry. The time-consuming and intricate nature of attaining approval for new therapies often inhibits patient access to such therapies within a reasonable period. These ceilings may also result in restrained investment into research and development hence causing sluggard entry of new treatments into the market.
Limited Awareness and Screening
- Being mindful of the lung cancer symptoms and the need for their timely diagnosis takes great effort. Otherwise, it may act as a barrier to the global lung cancer therapeutics market. A lot of people may not go for treatment in good time, hence the stage diagnosis may be too late. The influence of such a factor causes absence of early treatment demand, which in turn hinders the growth of the market for effective treatment alternatives.
Request Free Customization of this report to help us to meet your business objectives.
Lung Cancer Therapeutics Market Competitive Landscape
The competitive landscape of the global lung cancer therapeutics market is characterized by a diverse range of pharmaceutical and biotechnology companies focused on developing innovative therapies. Omron, Merck, Bristol-Meyers Squibb, AstraZeneca and Pfizer are some of the major companies in the industry and are heavily focused on development of new treatments. Primary focus of development is product line expansion targeted at the increasing needs of effectively treating lung cancer with targeted therapies and immunotherapy.
Top Player's Company Profiles
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- AstraZeneca PLC (UK)
- Merck & Co. Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Bristol Myers Squibb Company (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson (U.S.)
- Amgen Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- AbbVie Inc. (U.S.)
- GlaxoSmithKline plc (GSK) (UK)
- Sun Pharmaceutical Industries Ltd. (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Germany)
- Dr. Reddy's Laboratories (India)
Recent Development in Lung Cancer Therapeutics Market
- In September 2024, Roche declared that Phase III clinical trials for atezolizumab, a lung cancer drug in a combination treatment with chemotherapy, are completed successfully. The outcomes showed marked improvement in progression-free survival in patients with advanced non-small cell lung cancer (NSCLC), thus Roche decided to apply for an accelerated regulatory approval of this combination treatment.
- In August 2024, AstraZeneca’s new drug, osimertinib, has been approved by the Food and Drug Administration (FDA) for first-line treatment in advanced non-small cell lung cancer (NSCLC) with EGFR mutation. This is an important development as it hopes to improve patient outcomes by providing an alternative that is more effective than what is currently available and it meets the rising concerns for precision medicine in lung cancer management.
- In July 2024, Merck & Co. announced promising results from its latest clinical trial evaluating the combination of pembrolizumab and a novel adjuvant therapy for small cell lung cancer (SCLC). This innovative approach aims to improve overall survival rates, reinforcing Merck’s commitment to advancing treatment options for this aggressive cancer type.
Lung Cancer Therapeutics Key Market Trends
- Rise of Personalized Medicine in Lung Cancer Treatment: There is a notable tendency in the global lung cancer therapeutics market, which is toward personalized medicine. Such an approach employs genetic profiling and biomarkers to design tailored treatments to suit individual patients. This trend increases the effectiveness of treatment and reduces the risk of adverse events and hence the need for targeted therapies and immunotherapies that correspond to specific patient’s cancer is increasing.
- Integration of Immunotherapy in Treatment Regimens: The integration of immunotherapy into standard lung cancer treatment regimens is transforming patient care. Growing body of clinical evidence supports the effectiveness of immunotherapy in lung cancer treatment, and therefore healthcare providers are increasingly combining it with other therapies including chemotherapy and targeted therapies to increase the overall survival and the quality of life for lung cancer patients.
Lung Cancer Therapeutics Market SkyQuest Analysis
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global lung cancer therapeutics market is poised for significant growth due to advances in diagnostic techniques, innovative treatment options, and increased awareness of lung cancer. Government investments in healthcare infrastructure and the rising incidence of lung cancer are vital factors driving market expansion.
Given the growing need for personalized and effective cures, it can be said that more and more innovations will be witnessed in the ongoing convergence in research and development. And moreover, the specific sections of the market depending on the type of disease and type of treatment indicate that such lung cancer specific approaches are quite essential to deal with the problem, which is beneficial for both patients and medical care providers by offering ways of improved treatment.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 36.4 billion |
| Market size value in 2032 | USD 111.1 billion |
| Growth Rate | 13.2% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Lung Cancer Therapeutics Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Lung Cancer Therapeutics Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Lung Cancer Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Lung Cancer Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Lung Cancer Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Lung Cancer Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
